NEUTROLIS, INC.
Therapeutic agents that degrade neutrophil extracellular traps (NETs) to treat autoimmune and inflammatory diseases
- Sector
- Biotech
- Headquarters
- Boston, MA
- Founded
- 2017
- Latest Form D
- $3.5M, Jul 2025
- Total capital
- $28.1M
- Federal grants
- $461K
- 2 awards · 2020
- Rank in peer group#292 of 502
- Private capital raised
- $27.6M
- 3 Form D · last Jul 2025
- 15 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 11
- 29 pending · first 2020
- Rank in peer group#8 of 502
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$3.5M
- Private capital raisedForm D · SEC · 2nd filing$965K
- Private capital raisedForm D · SEC · 1st filing$23.1M
- Federal grantHealth and Human S · Phase I · Targeting Neutrophil Extracellular Traps for Acute Lung Injury$210K
- Federal grantHealth and Human S · Phase I · Genetic profiling of SLE patients with impaired NET degradation.$252K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
19months
from NEUTROLIS, INC.’s first federal award to its first private round.
- First federal award · Apr 2020
- Health and Human S · $252K
- First Form D · Dec 2021
- $23.1M · 1st Form D
- Awards before first raise
- 2 awards
An association in public records, not a cause or a prediction.
Standing among 502 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#8 · top 2%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Abdul Hakkim RahamathullahDirector, Executive Officer, PromoterNamed in SEC Form D filings
- Anthony Hakkim AiudiDirectorNamed in SEC Form D filings
- Gerald Hakkim ChanDirectorNamed in SEC Form D filings
- John Hakkim SundyDirectorNamed in SEC Form D filings
- Toby Hakkim FoxExecutive Officer, Director, PromoterNamed in SEC Form D filings
What it has protected
USPTO · 11 granted of 40- PendingDnase 1-LIKE 3 Engineered For Improved Expression And Use In TherapyUSPTOApplication 19129105
- PendingEngineering Of Dnase Enzymes For Manufacturing And TherapyUSPTOApplication 19465481
- GrantedEngineered Dnase Enzymes For Thrombosis TherapyUSPTOUS 12,565,642
Show all 40 patent records
- Dnase 1-LIKE 3 Engineered For Improved Expression And Use In TherapyJul 2, 2026 · Application 19129105Pending
- Engineering Of Dnase Enzymes For Manufacturing And TherapyJun 4, 2026 · Application 19465481Pending
- Engineered Dnase Enzymes For Thrombosis TherapyMar 3, 2026 · US 12,565,642Granted
- Dnase Enzymes Engineered For Improved StabilityJun 5, 2025 · Application 18840667Pending
- Engineered Human Extracellular Dnase EnzymesApr 24, 2025 · Application 18798042Pending
- Dnase Enzymes Engineered For Improved StabilityDec 5, 2024 · Application 18812252Pending
- DNASE1-LIKE 3 And Its Use In TherapyNov 14, 2024 · Application 18658758Pending
- Engineered Human Extracellular Dnase Enzymes For Drug Candidate SelectionNov 7, 2024 · Application 18655606Pending
- Dnase 1-LIKE 2 Engineered For Manufacturing And Use In TherapyApr 25, 2024 · Application 18546864Pending
- Engineering Of Dnase Enzymes For Manufacturing And TherapyDec 12, 2023 · US 11,840,712Granted
- Methods For Treating Or Preventing Tissue AdhesionsSep 28, 2023 · Application 17929074Pending
- Basic Domain-deleted DNASE1-LIKE 3 And Uses ThereofMar 9, 2023 · Application 17800950Pending
- Engineering Of Dnase Enzymes For Manufacturing And TherapyFeb 14, 2023 · US 11,578,314Granted
- Methods For Treating Or Preventing Tissue AdhesionsOct 11, 2022 · US 11,464,833Granted
- Engineered Human Extracellular Dnase EnzymesAug 18, 2022 · Application 17732927Pending
- Engineered Human Extracellular Dnase EnzymesJun 7, 2022 · US 11,352,613Granted
- Animal Model For Drug DevelopmentMay 5, 2022 · Application 17572257Pending
- Engineered Human Extracellular Dnase Enzymes For Drug Candidate SelectionJan 27, 2022 · Application 17427974Pending
- Methods Of Using DNASE1-LIKE 3 In TherapySep 30, 2021 · Application 17344442Pending
- Engineered Dnase Enzymes And Use In TherapySep 9, 2021 · Application 17193455Pending
- Methods Of Using DNASE1-LIKE 3 In TherapyJul 13, 2021 · US 11,058,724Granted
- Dnase Therapy For Intravascular Accumulation Of Extracellular DnaJun 29, 2021 · US 11,046,943Granted
- Dnase Therapy For Intravascular Accumulation Of Extracellular DnaJun 29, 2021 · US 11,046,942Granted
- Manufacturing And Engineering Of Dnase Enzymes For TherapyApr 27, 2021 · US 10,988,746Granted
- Engineered Dnase Enzymes And Use In TherapyOct 13, 2020 · US 10,801,019Granted
- Engineered Dnase Enzymes And Use In TherapyJun 30, 2020 · US 10,696,956Granted
- Dnase Enzymes Engineered For Improved StabilityApplication 63326499Pending
- Basic Domain-deleted DNASE1-LIKE 3 And Uses ThereofApplication PCTUS2021019048Pending
- Dnase 1-LIKE 2 Engineered For Manufacturing And Use In TherapyApplication 63150433Pending
- Dnase 1-LIKE 3 Engineered For Improved Expression And Use In TherapyApplication 63425106Pending
- Dnase Enzymes Engineered For Improved StabilityApplication PCTUS2023013680Pending
- Basic Domain-deleted DNASE1-LIKE 3 And Uses ThereofApplication 63064566Pending
- Biomarker And Precision Therapy For Autoimmune DiseaseApplication 63542824Pending
- Basic Domain-deleted DNASE1-LIKE 3 And Uses ThereofApplication 63040742Pending
- Engineered Dnase Enzymes And Use In TherapyApplication 16856943Pending
- Basic Domain-deleted DNASE1-LIKE 3 And Its Use In TherapyApplication 62978976Pending
- Engineered Human Extracellular Dnase Enzymes For Drug Candidate SelectionApplication PCTUS2020016490Pending
- Dnase 1-LIKE 3 Engineered For Improved Expression And Use In TherapyApplication PCTUS2023079602Pending
- Engineering Of Dnase Enzymes For Manufacturing And TherapyApplication PCTUS2019055178Pending
- Biomarker And Precision Therapy For Inflammatory DiseaseApplication PCTUS2024050228Pending
Related companies, and why
- Immunis, Inc.Similar federal contract value in Biotech · null in contracts
- Shift Pharmaceuticals Holdings, Inc.Similar federal contract value in Biotech · null in contracts
- Caradon Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Castle Creek Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
- Olema PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
- Veltion Therapeutics LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .